Proxibarbal

Identification

Generic Name

Proxibarbal

DrugBank Accession Number

DB13253

Background

Proxibarbal is a derivative of barbiturates, which has been used to treat migraines. Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia ¹.

Type

Small Molecule

Groups

Approved

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Proxibarbal (DB13253)

×

Close

Weight

Average: 226.232
Monoisotopic: 226.095356939

Chemical Formula

C₁₀H₁₄N₂O₄

Synonyms

• Proxibarbal

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Proxibarbal.
Acetazolamide	The risk or severity of CNS depression can be increased when Acetazolamide is combined with Proxibarbal.
Acetophenazine	The risk or severity of CNS depression can be increased when Acetophenazine is combined with Proxibarbal.
Agomelatine	The risk or severity of CNS depression can be increased when Agomelatine is combined with Proxibarbal.
Alfentanil	The risk or severity of CNS depression can be increased when Alfentanil is combined with Proxibarbal.
Alimemazine	The risk or severity of CNS depression can be increased when Alimemazine is combined with Proxibarbal.
Almotriptan	The risk or severity of CNS depression can be increased when Almotriptan is combined with Proxibarbal.
Alosetron	The risk or severity of CNS depression can be increased when Alosetron is combined with Proxibarbal.
Alprazolam	The risk or severity of CNS depression can be increased when Alprazolam is combined with Proxibarbal.
Alverine	The risk or severity of CNS depression can be increased when Alverine is combined with Proxibarbal.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Not Available

Categories

ATC Codes

N05CA22 — Proxibarbal

• N05CA — Barbiturates, plain
• N05C — HYPNOTICS AND SEDATIVES
• N05 — PSYCHOLEPTICS
• N — NERVOUS SYSTEM

Drug Categories

• Barbiturates, Plain
• Central Nervous System Agents
• Central Nervous System Depressants
• Hypnotics and Sedatives
• Nervous System
• Psycholeptics
• Pyrimidines
• Pyrimidinones

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Diazines

Sub Class

Pyrimidines and pyrimidine derivatives

Direct Parent

Barbituric acid derivatives

Alternative Parents

N-acyl ureas / Diazinanes / Dicarboximides / Secondary alcohols / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

Substituents

1,3-diazinane / Alcohol / Aliphatic heteromonocyclic compound / Azacycle / Barbiturate / Carbonic acid derivative / Carbonyl group / Carboxylic acid derivative / Dicarboximide / Hydrocarbon derivative

Molecular Framework

Aliphatic heteromonocyclic compounds

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

F97OMS297F

CAS number

2537-29-3

InChI Key

VNLMRPAWAMPLNZ-UHFFFAOYSA-N

InChI

InChI=1S/C10H14N2O4/c1-3-4-10(5-6(2)13)7(14)11-9(16)12-8(10)15/h3,6,13H,1,4-5H2,2H3,(H2,11,12,14,15,16)

IUPAC Name

5-(2-hydroxypropyl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione

SMILES

CC(O)CC1(CC=C)C(=O)NC(=O)NC1=O

References

General References

1. WHO Pharmaceuticals: Restrictions in Use and Availability (2001; 40 pages) View the PDF document [Link]

External Links

ChemSpider

16406

RxNav

83885

ChEBI

134928

ChEMBL

CHEMBL2105233

Wikipedia

Proxibarbital

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	23.5 mg/mL	ALOGPS
logP	-0.13	ALOGPS
logP	-0.16	Chemaxon
logS	-0.98	ALOGPS
pKa (Strongest Acidic)	7.18	Chemaxon
pKa (Strongest Basic)	-2.5	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	95.5 Å2	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	55.24 m3·mol-1	Chemaxon
Polarizability	21.35 Å3	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 23, 2017 20:38 / Updated at February 21, 2021 18:54